* Dare Bioscience Inc is expected to show a rise in quarterly revenue when it reports results on November 7 (estimated) for the period ending September 30 2024
* The San Diego California-based company is expected to report a 304.6% increase in revenue to $4.046 million from $1 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.
* LSEG's mean analyst estimate for Dare Bioscience Inc is for a loss of 73 cents per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the pharmaceuticals peer group is also "Buy".
* Wall Street's median 12-month price target for Dare Bioscience Inc is $13.00, above its last closing price of $3.97.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jun. 30 2024 -0.65 0.00 -0.88 Missed
Mar. 31 2024 -0.72 -0.72 -0.84 Missed -16.7
Jan. 1 0001 -1.60 -1.18 -0.72 Beat 38.8
Sep. 30 2023 -1.16 -1.18 -1.08 Beat 8.2
Jan. -1.21 -1.18 -1.20 Missed -1.7
1 0001
Mar. 31 2023 -1.22 -1.20 -1.08 Beat 10
Dec. 31 2022 -1.62 -1.64 -2.28 Missed -39
Sep. 30 2022 -1.35 -1.41 -0.96 Beat 31.9
This summary was machine generated November 6 at 14:01 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments